Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Tevimbra
Pharma
BeiGene finally snags FDA approval for PD-1 drug Tevimbra
Twenty months after the FDA's original target decision date, BeiGene has finally received the FDA’s go-ahead for its PD-1 inhibitor Tevimbra.
Angus Liu
Mar 15, 2024 8:39am
BeiGene added 1,400 employees as key cancer drugs expand
Feb 26, 2024 11:03am
Novartis returns PD-1 to BeiGene in another cancer drug divorce
Sep 19, 2023 9:10am
Novartis, BeiGene stage comeback with broader stomach cancer win
Apr 20, 2023 10:55am
BeiGene doubles sales on Brukinsa, tislelizumab strength
Feb 27, 2023 10:56am
ESMO: Merck's Keytruda-Lenvima flop hands rivals a win
Sep 8, 2022 1:44pm